欢迎使用辉瑞医谷移动端
马上下载      

Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

2019年1月24日 胃肠间质瘤

2014, 欧洲肿瘤内科学会(ESMO)指南

Subject: In 2012, there were 447 000 new cases of colorectal cancer (CRC) in Europe. CRC is the second most frequent cancer and represents 13.2% and 12.7% of all cancer cases in men and women, respectively. CRC was responsible for 215 000 deaths in Europe in 2012. This represents 11.6% and 13.0% of all cancer deaths in men and women, respectively [1]. Approximately 25% of patients present with metastases at initial diagnosis and almost 50% of patients with CRC will develop metastases, contributing to the high mortality rates reported for CRC. The CRC-related 5-year survival rate approaches 60%.

Sources

请注意: 点击资源链接后,您即将离开辉瑞医学信息网站。       

本网站仅医疗卫生专业人士使用 | 辉瑞中国医学信息部 产品咨询热线 400-910-0055
©2019 Pfizer | 有关声明 | 隐私政策 | 客户服务 | 友情链接 | 辽ICP备14012080号-1 | 证书编号:(辽)-非经营性-2018-0005